Table 3.
Tumor samples exhibiting alterations within the coding region of WWOX
| Tumor sample | Tumor type | Alteration of WWOX gene detected |
|---|---|---|
| PEO1 | Ovarian adenocarcinoma | Homozygous deletion of exons 4–8 |
| PEO1CDDP | Ovarian adenocarcinoma | Homozygous deletion of exons 4–8 |
| PEO4 | Ovarian adenocarcinoma | Homozygous deletion of exons 4–8 |
| PEO6 | Ovarian adenocarcinoma | Homozygous deletion of exons 4–8 |
| WX330 | SCLC | Homozygous deletion of exons 6–8 |
| NCI-H69 | SCLC | Homozygous deletion of exons 6–8 |
| PANC1 | Pancreatic ductal adenocarcinoma | Homozygous deletion of exons 7–8 |
| HOV25 | Primary ovarian tumor | Aberrant transcript lacking exons 5–8 |
| MOLT-4 | Acute lymphoblastic leukaemia (T cell) | Heterozygous Lys-182/Glu-182* |
| P3HR-1 | Burkitt lymphoma | Heterozygous Thr-111/Ser-111 |
| U-937 | Histiocytic lymphoma | Homozygous Trp-120/Trp-120 |
| OH5 Hela | Cervical carcinoma (Hela variant) | Homozygous His-314/His-314 |
| SAOS-2 | Osteosarcoma | Heterozygous Lys-182/Glu-182* |
| SK-OV-3 | Ovarian adenocarcinoma | Heterozygous Lys-182/Glu-182* |
| COR-L105 | NSCLC | Heterozygous Lys-182/Glu-182* |
| COR-L311 | SCLC | Heterozygous Lys-182/Glu-182* |
| NCI-H1672 | SCLC | Homozygous Glu-182/Glu-182* |
| colo11 | Primary colorectal tumor | Heterozygous Lys-182/Glu-182* |
| colo53 | Primary colorectal tumor | Heterozygous Arg-120/Trp-120 |
| colo95 | Primary colorectal tumor | Heterozygous Arg-120/Trp-120 |
Tumor cell lines and primary ovarian and colorectal tumors exhibiting homozygous deletion of WWOX exons, aberrant WWOX transcripts, or one of four cancer-associated missense polymorphisms (shown in bold in Table 1). Amino acid alterations are predicted from translation of the FORII or FORIII(*) sequences.